Ornidazole


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Amoebiasis 0.5 g twice daily for 5-10 days. Amoebic dysentery 1.5 g once daily for 3 days. Giardiasis 1-1.5 g once daily for 1-2 days. Trichomoniasis 1.5 g once daily for 5 days. Treat sexual partners concomitantly. IV Severe amoebic dysentery; Amoebic liver abscess Initial: 0.5-1 g, then 0.5 g 12 hrly for 3-6 days. Anaerobic bacterial infections Initial: 0.5-1 g, then 1 g/day in 1-2 divided doses for 5-10 days. Substitute w/ 500 mg 12 hrly PO as soon as possible. Surgical prophylaxis 1 g 30 mins pre-op.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to ornidazole or to other nitroimidazole derivatives.
Special Precautions
Renal and hepatic impairment. CNS diseases e.g. epilepsy or multiple sclerosis. May impair ability to drive or operate machinery. Pregnancy and lactation.
Adverse Reactions
Somnolence, headache, nausea, vomiting, dizziness, tremor, rigidity, poor coordination, seizures, tiredness, vertigo, temporary loss of consciousness and signs of sensory or mixed peripheral neuropathy, taste disturbances, abnormal LFTs, skin reactions.
Drug Interactions
Potentiates effect of coumarin-type oral anticoagulants. Prolongs the muscle-relaxant effect of vecuronium bromide.
ATC Classification
G01AF06 - ornidazole ; Belongs to the class of imidazole derivative antiinfectives. Used in the treatment of gynecological infections.
J01XD03 - ornidazole ; Belongs to the class of imidazole derivative antibacterials. Used in the systemic treatment of infections.
P01AB03 - ornidazole ; Belongs to the class of nitroimidazole derivatives antiprotozoals. Used in the treatment amoebiasis and other protozoal diseases.
Disclaimer: This information is independently developed by CIMS based on ornidazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in